Similarly, knowing that both PDTs and cannabis show promise for certain conditions independently does not tell you what happens when you package them together. Running shoes and protein shakes may each improve athletic performance, but selling them as a bundled program requires its own trial. Digital therapeutics play an important role in the healthcare ecosystem alongside clinician-delivered care, pharmaceuticals, and other non-DTx medical devices. This diagram provides a snapshot of a complex ecosystem and lists various types of interventions available for patient monitoring, diagnosis, treatment decisions, and ongoing care.
Providers are refining hybrid workflows that blend virtual visits with in-person follow-up, using remote monitoring devices to track chronic conditions like heart failure, diabetes, and COPD. Reimbursement frameworks are gradually aligning with these models, and health systems that standardize device data ingestion and clinical workflows see better outcomes and lower readmission rates. Product Library – To help key stakeholders understand and differentiate digital therapeutics from the thousands of other mobile health apps that are available, DTA developed this library to highlight evidence-based innovative DTx products. DTx products can address critical gaps in care for underserved populations, regardless of patient age, language, culture, income, disease state, or geography.
Canary Health
Read DTA’s report on the value of digital therapeutics for rural and underserved populations. Digital therapeutics are expanding into more therapeutic areas, driven by growing clinical evidence and regulatory acceptance. This expansion reflects DTx technology’s maturation and the pharmaceutical industry’s recognition of software’s potential to address previously unmet clinical needs.
Global Digital Therapeutics for Diabetes Market – 2025-2033
Recently, Noom expanded its offerings with Noom Med, a clinical program providing access to GLP-1 weight-loss medications and specialized medical support, while also targeting the enterprise market through partnerships with major health plans and employers. Medical cannabis care in the United States currently operates without the clinical guardrails that define standard pharmacotherapy. Patients receive product recommendations from dispensary staff rather than clinicians, dosing is largely self-directed, and cannabis use is rarely documented in electronic health records due to scheduling barriers and stigma.
Behavioral Health Engagement Tools
The report provides comprehensive statistics and analysis, offering valuable insights for stakeholders to capitalize on growth opportunities. Overall, the AI-enhanced OSA coach market is positioned for robust expansion, aided by technological advances and heightened global awareness of sleep health. Members have access to high-quality, clinically vetted inpatient treatment facilities, including RCA and Banyan.
- FDA Software as a Medical Device (SaMD) Framework DTx products cleared through FDA’s digital health pathways are subject to FDA promotional regulations similar to medical devices.
- If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.
- The products developed by DTA member companies address a wide variety of diseases and deliver an equally diverse array of interventions.
- Food and Drug Administration for treating specific mental health disorders (excluding devices marketed under pandemic-related emergency use authorization).
- Below is a helpful description of that license, along with a sampling of others most commonly offered.
- Treating Massachusetts as an active implementation site rather than a hypothetical proposal is another common misreading to guard against.
The company offers a spectrum of services ranging from guided meditation and sleep tools to on-demand behavioral health coaching and therapy. By integrating consumer-friendly wellness content with clinical mental health services, Headspace Health provides a scalable solution for individuals and organizations seeking to address stress, anxiety, and depression. FDA Software as a Medical Device (SaMD) Framework DTx products cleared through FDA’s digital health pathways are subject to FDA promotional regulations similar to medical devices. Staff representing FDA-cleared prescription digital therapeutics must understand claim limitations, off-label use restrictions, and fair balance requirements. Clinically validated software-based therapies and rapid diagnostics for infectious diseases and chronic condition markers are shortening time to diagnosis and enabling earlier interventions. Payors and providers are more open to reimbursing digital therapeutics when backed by peer-reviewed outcomes and integrated into care pathways.
- Identify risks early and receive alerts for underperforming patients to improve outcomes and prioritize care team resources where needed.
- Digital medicine, on the other hand, consists of software or hardware products, typically supported by evidence, to measure or intervene in the service of human health.
- Staff supporting these conversations must understand DTx reimbursement landscape and be capable of facilitating high-level business development conversations.
- While traditional medicines have revolutionized modern healthcare by targeting the biological mechanisms of disease, they often focus on one dimension of patient care—the physical symptoms.
- Digital therapeutics are clinically validated software programs designed to treat or manage specific health conditions.
- An industry-defining alliance fostering a more effective and inclusive community for advancing tech-enabled and virtual care.
To date, only a few clinically tested software devices have been authorized by the U.S. Food and Drug Administration for treating specific mental health disorders (excluding devices marketed under pandemic-related emergency use authorization). These include reSET for substance abuse disorder (10), reSET-O for opioid use disorder (11), Somryst for chronic insomnia (12, 13) and EndeavorRx for pediatric attention deficit hyperactivity disorder (14, 15). SaMDs and MMAs for treating mild cognitive impairment, Alzheimer’s disease, schizophrenia, autism, depression, social anxiety disorder, phobias and PTSD https://creaspace.ru/users/profile.php?user_id=31587 are in clinical trials (1, 3, 5, 16, 17) and may also come to market soon.
Neither type of application delivers clinical benefits and both have limited regulatory oversight from the FDA. While the new regulatory pathway lifts barriers to market for DTx products, in a way serving as an incentive for technological innovation, regulatory authorities have not entirely developed specific methodologies to evaluate the companies formally. Thus, for many DTx entities, it is still not clear as to how their exclusive algorithmic mechanisms will be evaluated.4 Figure 2 represents the USFDA’s regulatory framework for DTx. DTA developed the Policymaker & Payor DTx Evaluation Toolkit to provide a common language and process for HCDMs and DTx manufacturers to jointly use throughout DTx product evaluation and implementation processes. Global drugmaker Eli Lilly has entered into a definitive agreement to acquire clinical-stage biotech Kelonia Therapeutics, underscoring a major move into next-generation gene therapy to advance cancer treatment. MH has received grants from NIMH, NIA, Brain Initiative and Stanley Foundation for other projects.
Better Therapeutics is a prescription digital therapeutics company focused on developing nutritional cognitive behavioral therapy (nCBT) for the treatment of cardiometabolic diseases. Its flagship product, AspyreRx, is the first FDA-authorized CBT app for treating adults with type 2 diabetes. The company’s platform aims to address the behavioral root causes of chronic diseases, providing a scalable digital intervention that can be prescribed by physicians to improve glycemic control and overall health. Kaia Health is a global digital therapeutics company that provides evidence-based treatments for musculoskeletal (MSK) conditions and chronic obstructive pulmonary disease (COPD). The company utilizes advanced computer vision technology via smartphone cameras to provide real-time feedback on physical therapy exercises, ensuring correct form and safety.
Pelago combines evidence-based digital tools with live clinical support, giving members an easy, private way to change substance use habits. Ensure patients are prepared for surgery and supported throughout recovery with a robust library of configurable clinically validated care instructions and virtual physical therapy programs. Unlike traditional roles, you are not only managing medications—you are managing patient engagement, behavioral outcomes, and digital care pathways.